title: Amiloride directly inhibits growth factor receptor tyrosine kinase activity.
abstract: Addition of amiloride to A431 human epidermoid carcinoma cell membranes inhibited autophosphorylation of the epidermal growth factor (EGF) receptor. The tyrosine phosphorylation of histone H2B catalyzed by an affinity-purified preparation of EGF receptor was also inhibited by amiloride. The inhibition was noncompetitive with respect to histone but competitive with ATP, suggesting that amiloride may act as an ATP analogue which causes the formation of nonproductive enzyme-substrate complexes. The tyrosine phosphorylation of histone H2B catalyzed by the purified EGF receptor was inhibited by amiloride at concentrations identical to those previously reported to block EGF action on cell proliferation (Ki = 350 microM). Amiloride similarly inhibited the tyrosine phosphorylation of the human placental insulin receptor and the platelet-derived growth factor receptor of Swiss 3T3 cells. Immunoprecipitation of the EGF receptor from A431 cells labeled for 24 h with [32P]phosphate demonstrated that amiloride decreased the phosphorylation of the EGF receptor on serine and threonine residues and blocked the effect of EGF to cause phosphorylation of the receptor on tyrosine residues. Phosphoamino acid analysis of total cell proteins indicated that amiloride inhibited the increase in phosphotyrosine levels caused by EGF. We conclude that amiloride directly inhibits the tyrosine kinase activity of the receptors for EGF, insulin, and platelet-derived growth factor in in vitro and can mediate such actions in vivo. This effect of amiloride demonstrates that it is unsuitable as a drug to test the hypothesis that the stimulation of the Na+/H+ antiporter is essential for mitogenic signaling by growth factor receptors.
authors.forename: R J
authors.initials: RJ
authors.lastname: Davis
authors.forename: M P
authors.initials: MP
authors.lastname: Czech
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000584:Amiloride / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive; D002294:Carcinoma, Squamous Cell; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors; D006657:Histones / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D051379:Mice; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D011719:Pyrazines / Q000494:pharmacology*; D011972:Receptor, Insulin / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism*; D017479:Receptors, Platelet-Derived Growth Factor; D012964:Sodium / Q000378:metabolism
chemical_list: D006657:Histones; D047428:Protein Kinase Inhibitors; D011719:Pyrazines; D011956:Receptors, Cell Surface; D004815:Epidermal Growth Factor; D000584:Amiloride; D000255:Adenosine Triphosphate; D012964:Sodium; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D011972:Receptor, Insulin; D017479:Receptors, Platelet-Derived Growth Factor